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Abstract: Background: Chronic migraine is a common, highly disabling, underdiagnosed 
and undertreated entity of migraine. It affects 0.9%–2.2% of the general adult population. 
The present paper overviews the preclinical and clinical data regarding the therapeutic effect 
of onabotulinumtoxinA in chronic migraineurs. Methods: A literature search was conducted 
in the database of PubMed up to 20 May 2015 for articles related to the pathomechanism of 
chronic migraine, the mode of action, and the efficacy, safety and tolerability of 
onabotulinumtoxinA for the preventive treatment of chronic migraine. Results:  
The pathomechanism of chronic migraine has not been fully elucidated. The mode of action 
of onabotulinumtoxinA in the treatment of chronic migraine is suggested to be related to  
the inhibition of the release of calcitonin gene-related peptide and substance P in the 
trigeminovascular system. Randomized clinical trials demonstrated that long-term 
onabotulinumtoxinA fixed-site and fixed-dose (155–195 U) intramuscular injection therapy 
was effective and well tolerated for the prophylactic treatment of chronic migraine. 
Conclusions: Chronic migraine is a highly devastating entity of migraine. Its exact 
pathomechanism is unrevealed. Two-third of chronic migraineurs do not receive proper 
preventive medication. Recent clinical studies revealed that onabotulinumtoxinA was  
an efficacious and safe treatment for chronic migraine. 
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1. Introduction 
Migraine is a highly disabling primary headache disorder that affects 6%–10% and 17%–25% of  
the adult population in men and women, respectively, with a male to female ratio of 1:3 [1–3].  
The disease is ranked among the top 10 causes of disability worldwide [2,4]. Migraine headache is 
characterized by unilateral, throbbing and pulsating, moderate or severe pain, accompanied by nausea 
and vomiting, and photo- and phonophobia [5]. The two main subtypes are migraine without and with 
aura [5]. One of the most serious conditions related to migraine headache is chronic migraine (CM), 
which definitely influence the quality of life of the patients and represents a worldwide societal  
burden [6,7]. CM occurs more frequently in women than in men (2.5–6.5 times more often in female 
compared to male patients) [8]. The importance of CM as a disease is reflected by the fact that  
the International Classification of Headache Disorders (ICHD) 3 beta has recently categorized it as  
an independent disease entity [5]. CM patients lose 4.6 h per week because of the headache [9].  
The CM-related healthcare resource was higher than that related to episodic migraine [6].  
The estimated prevalence of CM ranges from 0.9% to 2.2% in the general population [10–12].  
The definition and the diagnostic criteria of CM are the following: headache (tension-type-like and/or 
migraine-like) occurring on 15 or more days per month for more than three months, fulfilling  
the criteria of migraine with or without aura on at least eight days per month [5]. The exact 
pathomechanism of CM is still unrevealed; however, altered brain energy metabolism and central 
sensitization process have been postulated to play crucial roles in its development [13]. The treatment 
of CM is likewise unsolved. Only around 33% of migraine patients receive proper preventive migraine 
treatment, e.g., antiepileptic drugs (topiramate, valproic acid/sodium valproate) or antidepressants 
(amitriptyline) [10,14–16]. In October 2010, the Food and Drug Administration (FDA) approved 
onabotulinumtoxinA (OBOT-A) fixed-site and fixed-dose (155–195 U) intramuscular injection as  
a preventive treatment for CM [17]. The supposed mode of action of OBOT-A in CM includes  
the inhibition of calcitonin gene-related peptide (CGRP) and substance P (SP) release in  
the trigeminovascular system (TS) [8,13]. The pooled analysis of Phase III REsearch Evaluating 
Migraine Prophylaxis Therapy (PREEMPT)-1 and PREEMPT-2 studies revealed that long-term 
treatment with OBOT-A was highly effective in reducing headache frequency and was generally safe 
and well tolerated as a prophylactic medication of CM [7,18–20]. 
The present paper reviews the mode of action, efficacy, safety and tolerability of OBOT-A in  
the prophylactic treatment of CM patients. 
2. Materials and Methods 
A literature search was conducted in the database of PubMed up to 25 May 2015 for articles related 
to pathomechanism of chronic migraine, the mode of action of OBOT-A and the efficacy, safety and 
tolerability of OBOT-A for preventive treatment of chronic migraine. 
Toxins 2015, 7 2661 
 
 
3. Results 
3.1. Pathomechanism of CM 
The pathomechanism of migraine is still not fully understood. One of the leading hypotheses is related 
to the activation of the TS [21]. The “skeleton” of the TS consists of the trigeminal ganglion (TRIG), 
which forms a bridge between the cortical and meningeal vasculature, and the second-order nociceptive 
neurons in the brainstem [21]. This hypothesis unifies the vascular and neuronal theories of migraine, 
defining the disease as a neurovascular disorder [22,23]. The neurobiological background of the clinical 
picture of migraine is proposed to include the peripheral and central sensitization within the TS. During 
this process, the vasoactive neuropeptides such as CGRP and pituitary adenylate cyclase-activating 
polypeptide (PACAP) are released from the TRIG both from the peripheral and central arches of  
the pseudounipolar neurons [24]. These vasoactive neuropeptides evoke neurogenic inflammation, 
leading to peripheral sensitization in the dura mater and central sensitization in the trigemino-cervical 
complex (TCC) [25–29]. The TCC represents a part of the brainstem, which involves the caudal part of 
the trigeminal nucleus caudalis (TNC) and the dorsal horn of the C1-2 segments of the cervical spinal 
cord [26]. Peripheral sensitization explains the throbbing nature of migraine headache and the worsening 
of the headache due to physical activity during a migraine attack [30,31]. On the other hand, central 
sensitization reflects the allodynia and the pericranial muscle tenderness during the painful headache 
periods [30,32–34]. 
Allodynia as a clinical marker of the central sensitization—which is an abnormal sensory state where 
normally innocuous stimuli are felt as painful—is a frequent accompanying sign during migraine  
attack [30,35,36]. The incidence of cutaneous allodynia is higher in patients with CM compared to 
episodic migraineurs [37]. Cutaneous allodynia might be an independent predictor of the chronification 
of migraine [38]. 
The risk of developing CM was higher in those migraine patients who had high migraine attack 
frequency (5–9 days vs. less than four days of headache per month) [39]. The other modifiable risk 
factors for CM include obesity (body mass index above 30 kg/m2), anxiety and depression, stressful life 
events, heavy caffeine consumption, smoking and medication overuse [40]. It has been revealed that the 
presence of depression (from moderate to severe intensity) is associated with an increased  
risk of the development of CM [41]. CM is associated with comorbid conditions, e.g., psychiatric 
(anxiety—30.2%, depression—30.2%), pain (chronic pain—31.5%, arthritis—33.6%), respiratory 
(asthma—24.4%, sinusitis—45.2%), cardiovascular (hypertension—33.7%) and metabolic  
(obesity—25.5%) disorders [40]. It is also a meaningful finding that the severity of allodynia was  
the highest in CM patients with comorbid depression [37,42]. It seems that there is a bidirectional 
connection between CM and episodic migraine subtypes. The AMPP (American Migraine Prevalence 
and Prevention) study revealed that migraine chronification occurred in association with an increased 
intake of abortive migraine medications [40]. Vice versa, the withdrawal of these drugs reversed CM 
state to episodic migraine [40]. 
The exact pathomechanism of CM is unknown [40]. There are some preclinical and clinical data 
pointing out the impact of altered brain structures and metabolism, cortical hyperexcitability and  
the central sensitization of the TS in the pathogenesis of CM. Neuroimaging studies revealed  
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the reduction of cerebral gray matter in the pain matrix, such as that of the anterior cingulate cortex,  
the reduction of which showed a positive correlation with migraine attack frequency [13]. In the early 
1900s, Weiller and his group elegantly demonstrated that during a spontaneous migraine attack,  
specific-brainstem nuclei (e.g., periaqueductal gray matter (PAG), locus coeruleus and raphe nuclei) 
showed increased activity, as revealed by positron emission tomography (PET) [43]. Furthermore, iron 
accumulation in the PAG was observed in migraine, which showed a correlation with disease  
duration [44]. Human PET studies concerning brain metabolism and hyperexcitability suggested that  
the orbitofrontal and temporal cortices might play a role in the initiation of the CM [13]. 
3.2. Supposed Mode of Action of OBOT-A in Chronic Migraine Therapy 
Botulinum neurotoxin-A—a potent purified neurotoxin complex produced by anaerobic bacteria 
Clostridium botulinum—affects the nervous system within the neuromuscular junctions by means of  
a specific cleavage of the soluble N-ethylmaleimide-sensitive factor (NSF)-attachment protein receptor 
complex (SNARE)-like synaptosomal-associated protein of 25 kDa (SNAP-25) [45,46] (Figure 1).  
The result of this multistage process is the disruption of pain neurotransmission, including  
the inhibition of the release of CGRP, SP and glutamate [45]. 
Within the sympathetic sudomotor C nerve fiber terminals surrounding the sweat glands, acethylcholine 
is co-localized with CGRP [47,48]. CGRP is capable of enhancing cholinergic sweating [49,50]. Clinical 
examinations demonstrated that botulinum toxin treatment can reduce focal (palmar and axillary) 
hyperhidrosis with a relatively long duration of effect [51]. CGRP is widely distributed in  
the sensory system, including also the dorsal root ganglia and the trigeminal ganglia [52–54]. Preclinical 
and clinical studies revealed that botulinum neurotoxin exerted analgesic effect in inflammatory as well 
as neuropathic pain via direct and indirect peripheral and central nociceptive pathways through  
the inhibition of the release of neuropeptides such as CGRP [55]. 
 
Figure 1. Schematic presentation of the mode of action of OBOT-A in CM. (modified by 
Ref. [20]) Abbreviations: CGRP, calcitonin gene-related peptide; OBOT-A, onabotulinumtoxinA; 
NK1, neurokinin1; and SNAP-25, synaptosomal-associated protein of 25 kDa. 
Preclinical studies revealed that OBOT-A has direct effect on peripheral sensitization and indirect 
effect on central sensitization [13]. OBOT-A inhibits evoked (by potassium chloride or capsaicin),  
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but not basal (unstimulated) release of CGRP in rat TRIG cell culture model [56]. Moreover,  
the proton-regulated release of CGRP from cultured primary trigeminal ganglion neurons utilizes  
a different mechanism than the calcium- and SNAP-25-dependent pathways, which mechanism in this 
case cannot be inhibited by OBOT-A [57]. Botulinum toxin influences the release of SP in embryonic 
rat dorsal root ganglion neurons [58]. Recently, it has been revealed that OBOT-A inhibits mechanical 
nociception in peripheral trigeminovascular neurons [59]. CGRP has a crucial role in the peripheral and 
central sensitization in migraine [24,25,60,61]. Cortical spreading depression (CSD) is a strong,  
slowly-propagating depolarization of neuronal and glial elements of the cortex, accompanied by  
the depression of electroencepehalographic activity and by a high amount of increase in the levels of 
extracellular potassium ion [26]. In the peripheral part of the TS (i.e., vasculature of the cerebral dura 
mater and pia mater), the consequences of the CSD include the stimulation of trigeminal nociceptors. 
After this process, vasoactive neuropeptides such as CGRP, PACAP and SP are released through  
the peripheral branches of TRIG, leading to neurogenic inflammation and peripheral sensitization  
(Figure 2). 
 
Figure 2. Schematic presentation of the trigeminovascular system. (modified by  
Refs. [22,23,26]) Abbrevations: CGRP, calcitonin gene-related peptide; CSD, cortical 
spreading depression; LC, locus coeruleus; NRM, nucleus raphe magnus; PACAP, pituitary 
adenylate-cyclase activating polypeptide; PAG, periaqueductal gray matter; SP, substance 
P; TCC, trigemino-cervical complex; and TRIG, trigeminal ganglion. 
Neuron-glia interactions in the TRIG represent a novel aspect of the trigeminovascular  
hypothesis [62,63]. The release of CGRP during neuronal activation of the TRIG stimulates  
the satellite glia cells, which in turn release proinflammatory cytokines, thereby further modulating  
the neuronal response [62–65]. This process is suggested to participate in the maintenance of CM [66]. 
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The central part of the TS projects toward the TCC and activates the second-order nociceptive neurons, 
which convey the information from the brainstem to the thalamus [24,26]. There are data reflecting that 
CGRP is involved in the activation of second-order nociceptive neurons in the TCC [24,25,60]. CGRP 
is able to facilitate glutamatergic neurotransmission in the dorsal horn of the spinal cord [67]. 
Furthermore, CGRP influences the discharge frequency of wide dynamic range neurons in the spinal 
cord, leading to the consequent initiation of central sensitization [60,68]. CGRP might modulate  
the activation of TS through its action within the PAG, where CGRP acts on calcitonin receptor-like 
receptor (CLR) and receptor activity-modifying protein (RAMP)-1 receptor [60]. 
In a recent clinical study, it has been revealed that interictal levels of CGRP in the plasma of patients 
with CM were decreased following OBOT-A treatment [69]. Furthermore, the authors concluded that 
CM patients who responded well to OBOT-A treatment had higher pretreatment CGRP plasma levels 
compared to non-responders [69]. 
CGRP is a migraine-related neuropeptide, which play roles in both the peripheral and central 
sensitization in the TS, as well as in the neuron-glia interaction in the TRIG. OBOT-A may inhibit  
the release of CGRP. 
3.3. Therapeutic Indications of OBOT-A in Primary Headaches 
The aim of migraine treatment is not just relieving pain and reducing migraine attack frequency but 
also preventing the progression towards the chronification of migraine [70]. The first implication 
suggests that the therapeutic potential of OBOT-A administration in headache treatment stems from  
the case of headache sufferers who reported improvement of their headaches after its cosmetic use for 
facial wrinkles [8,18]. After this observation, numerous (open label and randomized) clinical trials were 
conducted in different types of headaches (e.g., chronic daily headache, tension-type headache, episodic 
and CM) [18]. Finally OBOT-A has been approved only in the treatment of CM [19]. 
3.4. Technique of Injection of OBOT-A in CM 
The principle of the technique using OBOT-A is the administration of fixed-site and fixed-dose 
injections. The required technique includes at least 31 injection sites across the head and neck  
regions [71]. The recommended fixed-sites and fixed-doses (totally 155–195 units (U)/cycle) are  
the follows: corrugator muscle: 5 U (each side), procerus muscle: 5 U (one side), frontal muscle: 10 U 
(each side), temporalis muscle: 20 U (each side), occipitalis muscle: 15 U (each side), cervical paraspinal 
muscle: 10 U (each side), trapezius muscle: 15 U (each side) [8]. The value of U represents an estimated 
dose of intraperitoneally injected toxin lethal for 50% of the female Swiss Webster mice (weighing  
18–20 grams) [46]. The purpose of this procedure is to reach the supraorbital, supratrochlear and 
auriculotemporal branches of the trigeminal nerves and the greater and lesser occipital nerve branches, 
as well as the sensory rami from the cervical spinal segments C3-C5 [8]. The recommended needle size 
is a 30-gauge, 0.5-inch needle, which should be inserted at a 45-degree angle to the plane of the head 
and neck [8]. The repeated injection schedule is every 12 weeks [19]. 
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3.5. Efficacy of OBOT-A in Treatment of CM 
The largest randomized clinical trials that evaluated the efficacy of OBOT-A in CM were  
the PREEMPT-1 and PREEMPT-2 studies [19]. Analysis of the primary endpoint for the efficacy from 
the pooled data set revealed that OBOT-A significantly reduced the number of headache days per  
28-day cycle relative to placebo at week 24 (−8.4 vs. −6.6; p < 0.001) [19]. The secondary endpoints 
were the following: mean change from baseline in frequency of migraine days (p < 0.001); frequency of 
moderate or severe headache days (p < 0.001); cumulative hours of headache and headache days  
(p < 0.001); frequency of headache episodes (p < 0.009); frequency of migraine episodes (p = 0.004); 
and the proportion of patients with a severe Headache Impact Test-6 score (p < 0.001) [19].  
In the OBOT-A-treated group, the intake of triptans as acute pain medication was significantly less 
compared to the placebo group at week 24 (p < 0.001) [19]. In PREEMPT 24-week pooled subgroup 
analysis of CM patients with medication overuse revealed that the change from baseline in the frequency 
of acute headache medication intakes was not statistically significant, except for triptan intakes [72]. 
A single-center, double-blind, comparative pilot study revealed that OBOT-A and topiramate  
(an antiepileptic drug used for migraine prevention with Level A evidence) demonstrated similar 
efficacy in the prophylaxis of CM [73–75]. Likewise, a multi-center, double-blind, comparative pilot 
study demonstrated that OBOT-A and topiramate had similar efficacy (by week 26 in the reduction of 
headache days per month compared with baseline) in patients with CM [76]. The secondary subgroup 
analysis of the data of CM patients who received all five treatment cycles of OBOT-A and completed 
the PREEMPT study demonstrated that the percent of patients with a higher than 50% reduction from 
baseline of the frequency of headache days was significantly greater for the OBOT-A-only group at 
week 56 [10]. A study analyzing long-term experience with OBOT-A in CM demonstrated that after  
an average of two years treatment with OBOT-A in responder CM patients the need for acute pain 
medication was decreased by 53% and emergency visits were reduced by 61% [77]. In a recent clinical 
trial, CM patients with medication overuse were studied after a five-day-long withdrawal period with  
150 U OBOT-A injection, which confirmed the efficacy of OBOT-A [78]. Results of another clinical 
study in which OBOT-A was used in the dose of 155 U, in accordance with the PREEMPT study 
protocol, showed that the number of headache days per month and the acute medication intakes 
decreased significantly in the treatment group [79]. A recent prospective post-marketing cohort analysis 
in a real-life clinical setting demonstrated that OBOT-A significantly reduced the number of headache 
and migraine days, and showed a capability to increase the numbers of headache-free days [80]. 
3.6. Tolerability and Safety of OBOT-A in Treatment of CM 
Based on the PREEMPT pooled data, the total treatment-related adverse events (AEs) of OBOT-A 
treatment in CM were 29.4% vs. 12.7% for placebo, and included neck pain (6.7% vs. 2.2%), muscular 
weakness (5.5% vs. 0.3%), eyelid ptosis (3.3% vs. 0.3%) and injection site pain (3.2% vs. 2.0%) [19]. 
These AEs were mild-to-moderate and transient. Serious AEs occurred in 4.8% of the CM patients on 
therapy compared to 2.3% for those in the placebo group, and no death was reported [19]. 
Data from pooled analysis of the safety and tolerability data of two phase 2 and two phase 3  
double-blind, placebo-controlled trials (1997 CM patients, who received more than one dose of  
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OBOT-A on average dose of 163 U per treatment cycle) revealed that the majority of the patients 
(72.9%) presented at least one AE. The most prevalent AEs were neck pain (12.6%), muscle weakness 
(8%), musculoskeletal stiffness (6.1%) and eyelid ptosis (4.6%) [81]. 
In view of immunogenicity, OBOT-A as a neurotoxin (bacterially derived protein) can be associated 
with the development of toxin-neutralizing antibodies. Based on the 496 analyzable plasma  
samples achieved from OBOT-A-treated patients, none was shown to be positive for neutralizing  
antibodies [8,19,81]. 
The above analysis confirmed the favorable safety and tolerability profile of OBOT-A in  
the prophylactic treatment of CM. 
4. Discussion 
CM is a highly disabling chronic pain syndrome, which represents the severe end of the episodic 
migraine spectrum. The chronification of migraine is influenced by medication overuse as well as 
psychiatric comorbidities, such as depression and anxiety. A cross-sectional study analyzed  
the comorbid psychiatric conditions, such as depression, stagnation syndrome and overattachment in 
chronic migraineurs [82]. The study confirmed that chronic migraineurs with higher perceived disability 
compared to those with lower perceived disability expressed higher depression scores on  
the Center For Epidemiologic Studies Depression Scale (21.61 + 8.98 vs. 10.63 + 4.79), as well higher 
stagnation scale scores (75.55 + 31.90 vs. 42.33 + 24.93) [82]. In a clinical study, women with CM with 
higher total scores on affective dysregulated temperamental component demonstrated higher scores on 
Beck Hopelessness Scale and Suicidal History Self-Rating Screening Scale [83]. However, the analysis 
of functional polymorphisms of genes (MAO-A3, CYP1A2*1F, GNB3) proposed to be associated with 
hopelessness and suicidal risk did not confirm associations [83]. Risk factors for chronification include 
young age at onset, frequent migraine attacks at baseline, mood disturbances (e.g., depression),  
as well as the presence of cutaneous allodynia [38]. To reduce the risk of migraine chronification, proper 
prophylactic anti-migraine drugs in appropriate doses should be used, and attention should also be paid 
to concomitant factors such as depression, hypertension and obesity [84]. When the episodic state of 
migraine is transformed to chronic state, treatment options become very limited. The observation 
originating from the cosmetic (anti-wrinkle) use of OBOT-A indicating that it may harbor therapeutic 
potential in headache disorders gave a new hope to CM sufferers. Several early reports opened up  
new fields of research concerning the potential modes of action of OBOT-A in the treatment of  
primary headaches. 
The etiology of CM is supposed to be multifactorial with both genetic and environmental components 
proposed to play a role in it. The exact pathomechanism and genetic background of CM is still unknown; 
however, the overactivation of the TS, the central and peripheral sensitization processes as well as  
the effects of vasoactive neuropeptides may take a part in the pathogenesis. Based on  
the proposed pathomechanism, the inhibition of release of CGRP and other neuropeptides from  
the trigeminal system by OBOT-A provides a new possibility for the prophylactic treatment of CM. 
Recent clinical studies supposed that CGRP might be a potential biomarker of the responsiveness of CM 
patients to OBOT-A treatment [69]. The pooled analyses proved the favorable efficacy and good safety 
profile with low rate of AEs of OBOT-A therapy in CM. Furthermore, the results from clinical studies 
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showed that OBOT-A was also effective and well tolerated in CM patients with comorbid  
depression [17]. Follow-up experience with OBOT-A suggests that three-quarters of CM patients have 
long-term response after one year [77]. The recommended injection schedule is every 12 weeks, 
however, the long-term follow-up revealed that after one year the injection regimen could be delayed, 
though not stopped [77]. Based on an Italian pilot study, CM has a huge economic impact. The study 
demonstrated that the direct mean annual cost of CM was 2250.0 euro vs. 523.6 euro per patient with 
episodic migraine [85]. Furthermore, a large study (the International Burden of Migraine Study) 
involving five European countries (UK, France, Germany, Italy and Spain) revealed that the total annual 
cost of the CM vs. episodic migraine was higher in all five countries [86]. A cost-effectiveness survey 
demonstrated that OBOT-A treatment reduced the headache days by 38 days per year that is associated 
with a high economic impact [87]. Important clinical aspects regarding the medical care of CM patients 
include not only the efficacy and safety of a drug, but also the responder and the discontinuation rates, 
as well as the health-related quality of life [88]. OBOT-A does fulfill the above criteria in the treatment 
of CM. 
5. Conclusions 
Up until today, there is no exact explanation for the pathomechanism of CM, and the establishment 
of an efficacious treatment for CM patients represents a big challenge for the both the researchers and 
the medical team. Overall, we can consider OBOT-A as an effective, safe and well-tolerable prophylactic 
treatment for CM. Currently, it is the one and only FDA-approved preventive medication for chronic 
migraineurs. The ultimate goals for the research in the field of primary headaches are to find their genetic 
backgrounds, to determine the full scope of their pathomechanism, and to expand the therapeutic options 
of OBOT-A in the different headache conditions. 
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